Home Ingredients Coluracetam (BCI-540 / MKC-231)
CognitiveMood & Mental HealthStress & Anxiety

Coluracetam (BCI-540 / MKC-231)

Synthetic — high-affinity choline uptake racetam
Evidence Level
Preliminary
3 Clinical Trials
5 Documented Benefits
1/5 Evidence Score

Tetrahydrofuro-quinoline racetam developed by Mitsubishi Tanabe Pharma (1990s) for Alzheimer's. Failed AD endpoints; in-licensed by BrainCells Inc 2006 for major depressive disorder + comorbid anxiety. Phase IIa trial in 101 patients with MDD+GAD reported subgroup benefit (-12.2 vs -5.5 HAM-D, p<0.008) but trial NEVER PEER-REVIEW PUBLISHED. Company appears defunct. Unique HACU enhancement in damaged neurons.

Studied Dose BrainCells PHASE IIa: 240 mg/day (80 mg × 3). NOOTROPIC: 5-80 mg per dose, 1-3×/day. Take with food (lipophilic). NOTE: Phase IIa NEVER peer-review published (press release only). NO FDA approval.
Active Compound Coluracetam (2-(2-oxopyrrolidin-1-yl)-N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)acetamide, BCI-540, MKC-231) — bioisostere of 9-amino-tetrahydroacridine class

Benefits

Depression with comorbid anxiety — UNPUBLISHED phase 2 only

An industry-sponsored phase 2 trial in adults with major depression and comorbid anxiety reportedly showed substantial depression improvements (roughly double the placebo response) over 6 weeks. Critical caveats: this trial was NEVER published in peer-reviewed literature, the sponsoring company is now defunct, and results are known only through press releases. Should be treated with significant skepticism. There is no validated clinical use case for coluracetam in depression.

Supported by Trial 1

Choline uptake enhancement — including damaged neurons

Coluracetam is unusual among racetams in that it improves choline uptake in damaged cholinergic neurons, not just healthy ones. Animal studies show recovery of memory deficits and neurochemistry in models with chemically-induced cholinergic damage. Theoretically interesting for conditions involving cholinergic neuron damage (Alzheimer's, certain dementias), but no human translation has been completed. Mechanism is intriguing; clinical relevance remains preclinical.

Supported by Trial 2, Trial 3

AMPA receptor potentiation

Coluracetam is described as having dual actions: choline uptake enhancement plus AMPA receptor potentiation (a glutamate receptor pathway). This bifunctional mechanism is theoretically attractive for combined mood and cognitive effects without acting on serotonin or norepinephrine pathways — relevant for SSRI/SNRI non-responders if it worked clinically. But the clinical translation never materialized due to publication failure of the phase 2 trial.

Supported by Trial 3, Trial 1

Phencyclidine model in animals — preclinical only

In rats, coluracetam antagonizes phencyclidine-induced behavioral deficits and protects septal cholinergic neurons. Theoretically relevant to schizophrenia or NMDA-related cognitive impairment. This is preclinical animal evidence with no human translation. Mentioned here for mechanistic completeness, not as evidence supporting any clinical claim — animal models often fail to translate, particularly in psychiatric contexts.

Supported by Trial 2, Trial 3

Subjective visual enhancement — anecdotal

Coluracetam users frequently report enhanced color perception, contrast, and visual clarity ('hyper-vivid vision'). This subjective effect is unique among racetams and has driven much of the supplement-market interest. Mechanism is unclear — possibly related to cholinergic effects on visual cortex or AMPA modulation of sensory processing. Not formally studied in clinical trials. Treat as anecdotal — interesting if you experience it, but not reliable across users.

Supported by Trial 2, Trial 3

Mechanism of action

1

High-affinity choline uptake (HACU) enhancement — unique in damaged neurons

Coluracetam selectively enhances HIGH-AFFINITY CHOLINE UPTAKE — rate-limiting step in acetylcholine synthesis. Distinguishing feature from other racetams: improves HACU even in NEURONS WITH DAMAGED CHOLINE TRANSPORT (Murai 1994). Provides theoretical basis for cognitive recovery in pathological states beyond pure enhancement.

2

AMPA receptor positive modulation

Coluracetam acts as AMPA receptor positive allosteric modulator (similar to aniracetam). Combined with HACU enhancement, provides 'bifunctional' mechanism per BrainCells positioning. Mechanism for proposed mood effects via enhanced glutamatergic-mediated synaptic plasticity and BDNF release.

3

Glutamate cytotoxicity protection (neuroprotection)

Akaike 1998 demonstrated MKC-231 protects cultured cortical neurons against glutamate cytotoxicity. Mechanism: probably indirect via cholinergic restoration and AMPA modulation reducing excitotoxic damage. Theoretical relevance to ischemia, neurodegeneration.

4

BBB penetration via lipophilicity

Tetrahydrofuroquinoline structure provides good BBB penetration. Crosses readily; CNS effects achievable at modest doses. Pharmacokinetics less well-characterized than other racetams due to limited published clinical research.

Clinical trials

1
BrainCells Phase IIa MDD+GAD (UNPUBLISHED)
PubMed

Phase IIa exploratory trial conducted by BrainCells Inc 2009-2010. Press release only (BCI-PR-06142010); NEVER published in peer-reviewed literature.

101 patients with major depressive disorder (MDD) AND comorbid generalized anxiety disorder (GAD). 6-week randomized double-blind placebo-controlled study. BCI-540 240 mg/day (3x80 mg) vs placebo.

Per press release: depression symptoms in MDD+GAD subgroup improved -12.2 HAM-D points vs -5.5 placebo (p<0.008). Began separating from placebo at 4 weeks. Side effect profile similar to placebo. CRITICAL LIMITATIONS: NEVER published in peer-reviewed literature (~15 years post-trial); parent company BrainCells Inc appears defunct; results known only through archived press release and Wayback Machine. Cannot be verified; should be interpreted with significant skepticism. Demonstrates pattern of orphaned drug candidates with intriguing but unverifiable claims.

2
Murai 1994 — MKC-231 Working Memory in Cholinergic-Damaged Mice
PubMed

Foundational preclinical study (Murai S, Saito H, Abe E, Masuda Y, Odashima J, Itoh T 1994, J Neural Transm Gen Sect 98(1):1-13, doi:10.1007/BF01277590, PMID 7710736).

Mice with AF64A (ethylcholine aziridinium ion)-induced cholinergic neurotoxicity. Working memory deficits and hippocampal acetylcholine measured.

MKC-231 (coluracetam) AMELIORATED working memory deficits and RESTORED decreased hippocampal acetylcholine in cholinergic-damaged mice. UNIQUE FINDING: works in damaged neurons, not just healthy neurons. Foundational preclinical evidence supporting theoretical use in pathological cholinergic states (Alzheimer's, post-injury). Did not translate to successful Mitsubishi AD development.

3
Bessho 1996 — Water Maze Learning Effects in Rats
PubMed

Preclinical study (Bessho T, Takashina K, Tabata R, Ohshima C, Chaki H, Yamabe H, Egawa M, Tobe A, Saito K 1996, Arzneimittelforschung 46(4):369-373, PMID 8740080).

Rats with experimentally induced learning deficits. Water maze (Morris) navigation learning measured with MKC-231 treatment.

MKC-231 IMPROVED water maze learning deficits in rats. Effects observed at low doses without obvious side effects. Tacrine (control AChEI) at 0.1-3 mg/kg p.o. FAILED to ameliorate same deficits — distinguishing MKC-231's mechanism. Authors concluded: 'MKC-231 is a novel and quite unique compound, which improves the memory impairment induced by AF64A through the enhancement of HACU without any side effects at the effective doses.' Solid preclinical foundation.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated based on limited data; side effect profile similar to placebo in BrainCells Phase IIa.
Headache, nausea (occasional).
Anxiety, restlessness in some users.
Visual changes (color enhancement, contrast — typically considered benign or pleasant).
Long-term safety: minimal data due to limited publication.
Pregnancy/lactation: avoid.
Failed pharmaceutical development trajectory limits long-term safety data.

Important Drug interactions

Cholinergic medications: theoretical additive effects.
AMPAkines (other racetams, ampakines): theoretical additive effects.
Anticoagulants: theoretical mild antiplatelet activity (limited data).
Most medications: limited interaction data due to small clinical research base.
Compatible with most supplements; can stack with cholinergic precursors (alpha-GPC, citicoline).

More Cognitive Ingredients

Energy
Caffeine
Caffeine, a natural stimulant found in coffee, tea, and other plants, is commonly suppleme…
Cardiovascular
Omega-3 Fatty Acids
Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), an…
Cognitive
Vitamin B12
Vitamin B12, also known as cobalamin, is a water-soluble vitamin commonly supplemented as…
Immune Support
Zinc
Zinc, an essential trace mineral, is commonly supplemented in forms like zinc gluconate, a…

Frequently asked questions about Coluracetam (BCI-540 / MKC-231)

What is Coluracetam (BCI-540 / MKC-231)?

Tetrahydrofuro-quinoline racetam developed by Mitsubishi Tanabe Pharma (1990s) for Alzheimer's.

What does Coluracetam (BCI-540 / MKC-231) do?

Coluracetam selectively enhances HIGH-AFFINITY CHOLINE UPTAKE — rate-limiting step in acetylcholine synthesis. Distinguishing feature from other racetams: improves HACU even in NEURONS WITH DAMAGED CHOLINE TRANSPORT (Murai 1994). In clinical research, Coluracetam (BCI-540 / MKC-231) has been studied for depression with comorbid anxiety — unpublished phase 2 only, choline uptake enhancement — including damaged neurons, ampa receptor potentiation.

Who should take Coluracetam (BCI-540 / MKC-231)?

Coluracetam (BCI-540 / MKC-231) may be most relevant for people interested in cognitive, mood & mental health, stress & anxiety. It has been clinically studied for depression with comorbid anxiety — unpublished phase 2 only, choline uptake enhancement — including damaged neurons, ampa receptor potentiation. As with any supplement, consult your healthcare provider before starting, especially if you have medical conditions or take prescription medications.

How long does Coluracetam (BCI-540 / MKC-231) take to work?

In clinical trials, effects have been measured at 4 weeks of consistent use. Acute or same-day effects (where applicable) typically appear within hours, but most cumulative benefits — particularly those affecting biomarkers, mood, sleep quality, or chronic symptoms — require 4-12 weeks of regular use to fully assess. If you don't notice benefit after 12 weeks at the appropriate dose, it may not be your responder.

When is the best time to take Coluracetam (BCI-540 / MKC-231)?

For cognitive goals, Coluracetam (BCI-540 / MKC-231) is typically taken in the morning with breakfast for sustained daytime effects. Avoid late-day dosing if it affects your sleep. Always check product labeling and follow personalized guidance from your healthcare provider.

Is Coluracetam (BCI-540 / MKC-231) worth taking?

Coluracetam (BCI-540 / MKC-231) has preliminary clinical evidence (Evidence Level 1/5 on NutraSmarts) — based largely on traditional use or early research. Consider this an experimental option. Whether it's worth taking depends on your specific goals, what you've already tried, your budget, and your overall supplement strategy. The honest framing: no supplement is essential for most people, and lifestyle factors (sleep, exercise, diet, stress management) typically produce larger effects than any single supplement. Coluracetam (BCI-540 / MKC-231) is most worth trying if its evidence-supported uses align with your specific goals.

What is the recommended dosage of Coluracetam (BCI-540 / MKC-231)?

The clinically studied dose for Coluracetam (BCI-540 / MKC-231) is BrainCells PHASE IIa: 240 mg/day (80 mg × 3). NOOTROPIC: 5-80 mg per dose, 1-3×/day. Take with food (lipophilic). NOTE: Phase IIa NEVER peer-review published (press release only). NO FDA approval.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is Coluracetam (BCI-540 / MKC-231) used for?

Coluracetam (BCI-540 / MKC-231) is studied for depression with comorbid anxiety — unpublished phase 2 only, choline uptake enhancement — including damaged neurons, ampa receptor potentiation. An industry-sponsored phase 2 trial in adults with major depression and comorbid anxiety reportedly showed substantial depression improvements (roughly double the placebo response) over 6 weeks.